Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α<sub>5</sub>β<sub>1</sub> integrin monoclonal antibody (volociximab) in cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 207, doi. 10.1007/s00280-009-1023-8
- By:
- Publication type:
- Article